New Drug Targets Immune Balance to Fight Chronic Inflammation and Aging
Belgian biotech Coultreon raises $125M to advance an oral SIK3 inhibitor that rebalances inflammation rather than suppressing immunity outright.
Summary
Coultreon Biopharma has raised $125 million to develop COL-5671, an oral once-daily drug that targets a kinase called SIK3 to reduce harmful inflammatory signals like TNFα and IL-23 while boosting the anti-inflammatory molecule IL-10. Unlike existing biologics that broadly suppress the immune system, this approach aims to restore immune balance. The drug is initially being tested for psoriasis and ulcerative colitis, with Phase 1 and mid-stage trials planned toward a 2027 proof-of-concept. Researchers and investors see broader potential: chronic low-grade inflammation is a core driver of aging, and a therapy that corrects immune dysregulation without causing immunosuppression could have wide healthspan implications beyond treating specific autoimmune diseases.
Detailed Summary
Chronic inflammation is one of the most significant and underappreciated drivers of biological aging. It quietly degrades tissue function, accelerates disease, and shortens healthspan — yet most current treatments either ignore it or suppress the immune system so broadly that they create new risks. Coultreon Biopharma is betting $125 million that a more precise approach is possible.
The company's lead drug, COL-5671, works by inhibiting SIK3, a kinase enzyme involved in regulating inflammatory gene activity. Blocking SIK3 reduces pro-inflammatory cytokines TNFα and IL-23 while simultaneously increasing IL-10, a cytokine that promotes immune regulation and tolerance. This dual action — dampening harmful inflammation while reinforcing the body's own regulatory signals — is fundamentally different from biologics that simply block a single inflammatory pathway.
The drug is designed for once-daily oral dosing, a meaningful practical advantage over injectable biologics that dominate current autoimmune treatment. Early preclinical data shows favorable pharmacokinetics and sustained cytokine modulation. The molecule was originally developed by Galapagos before being transferred to Coultreon, and its safety profile has been backed by extensive toxicology work — enough to attract a high-profile investor syndicate including Sofinnova, Forbion, Novo Holdings, and Regeneron Ventures.
Clinical trials targeting psoriasis and ulcerative colitis are the near-term focus, with proof-of-concept data expected by 2027. But the broader thesis is about immune resilience as a longevity lever. If COL-5671 can durably correct immune dysregulation without trading inflammation for immunosuppression, it could represent a new category of medicine — one that treats disease today while building systemic resilience against aging-related decline.
Caveats are real: autoimmune drug development has a high failure rate at Phase 2, and elegant mechanisms frequently underperform in human trials. This remains early-stage science requiring clinical validation before any practical health implications can be drawn.
Key Findings
- COL-5671 inhibits SIK3 to reduce TNFα and IL-23 while boosting anti-inflammatory IL-10, targeting immune balance not suppression
- Once-daily oral dosing offers a practical advantage over costly injectable biologics currently dominating autoimmune treatment
- Phase 1 and mid-stage trials for psoriasis and ulcerative colitis are underway, with proof-of-concept targeted by 2027
- Chronic immune dysregulation is a recognized driver of aging biology, making this approach relevant beyond specific autoimmune diseases
- Oversubscribed $125M Series A signals strong investor confidence in SIK-targeting platforms for inflammation and healthspan
Methodology
This is a news report from Longevity.Technology covering a biotech funding announcement and pipeline update. The source is a credible longevity-focused trade publication. Evidence basis is company-disclosed preclinical and early clinical data, not yet peer-reviewed published trial results.
Study Limitations
All efficacy and safety data cited is preclinical or early-stage; Phase 2 human trial results are not yet available. The article relies on company statements and investor communications, which carry inherent promotional bias. Independent peer-reviewed publications on COL-5671 should be sought before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.